The European Commission approved ravulizumab (Ultomiris) for adults with paroxysmal nocturnal hemoglobinuria.
Alexion announced Wednesday that the European Commission approved ravulizumab (Ultomiris) for adults with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with eculizumab (Soliris) for at least the past 6 months.
Ravulizumab, to be sold under the name Ultomiris, is Alexion's long-acting C5 complement inhibitor, and offers less frequent administration than eculizumab. It is already approved for PNH in the United States, and last month, Alexion said the FDA accepted ravulizumab for priority review for the treatment of atypical hemolytic uremic syndrome (aHUS), with a decision expected by October 2019.
“At Alexion, our goal is to continue to improve the lives of people and families affected by PNH and other serious rare diseases,” said John Orloff, MD, executive vice president and head of research and development at Alexion in a statement. “We believe Ultomiris will become the new standard of care for patients with PNH by providing immediate and complete C5 inhibition, sustained throughout the 8-week dosing interval, and reducing the number of infusions per year from 26 with Soliris to only 6 or 7 with Ultomiris. We are also particularly pleased by the positive data showing patients can successfully transition from Soliris to Ultomiris.”
The European Commission approval is based on results from 2 phase 3 studies for PNH, which can cause a wide range of debilitating symptoms and complications, including thrombosis, which can occur throughout the body, resulting in organ damage and premature death. The studies included 441 patients who either had never been treated with a complement inhibitor before or who had been stable on eculizumab. The company said the efficacy of ravulizumab administered every 8 weeks was noninferior to the efficacy of eculizumab administered every 2 weeks on all 11 endpoints. Safety profiles were similar.
With biosimilar competition to eculizumab advancing, Alexion hopes to transition most of the patients already receiving the older eculizumab onto the newer ravulizumab in the near future.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.